Ketamine Therapy NYC Locations

IV ketamine for depression uses ketamine by an intravenous infusion outside its FDA-approved anesthetic indication. This is an off-label treatment decision. It is different from Spravato, the nasal esketamine product with specific adult depression indications and a REMS. The two treatments differ in formulation, dose planning, monitoring requirements and insurance pathways. Ask whether IV treatment is currently offered and which location, clinician and monitored setting would provide it.

A psychiatrist reviews the depressive illness, adequate previous treatment trials, current risk, other diagnoses and the alternatives. The assessment also reviews cardiovascular health, substance-use risks, pregnancy, liver history and medicines that may affect sedation or blood pressure. The clinician should explain why off-label IV ketamine is being considered and how outcomes and harms will be assessed. A suicidal crisis needs urgent safety care independently of a planned infusion.

Ask about the intended condition, expected benefit, uncertainty and alternatives such as established medicines, psychotherapy or a referral for brain stimulation. Off-label prescribing is a clinical decision. It does not mean FDA has approved a depression dose or schedule.

Ask who will administer and monitor the infusion, how breathing, blood pressure and alertness will be assessed, and how an emergency will be handled. Do not transfer onsite infusion information to an unsupervised home or compounded nasal regimen.

Before starting, agree on symptom and function measures, when benefit will be reviewed and what happens if there is little improvement or adverse effects. Session numbers and maintenance intervals must come from the treating program. They cannot be inferred from the Spravato label.

Track changes in mood, daily function, adverse effects and the duration of any improvement. If symptoms return between sessions, contact the treating psychiatrist rather than arranging an unsupervised dose increase. There is no Spravato-label maintenance schedule that can simply be applied to IV ketamine. A switch between formulations requires a new clinical and practical review.

IV ketamine for depression uses ketamine by an intravenous infusion outside its FDA-approved anesthetic indication. This is an off-label treatment decision. It is different from Spravato, the nasal esketamine product with specific adult depression indications and a REMS. The two treatments differ in formulation, dose planning, monitoring requirements and insurance pathways. Ask whether IV treatment is currently offered and which location, clinician and monitored setting would provide it.

Ketamine affects NMDA receptors and other brain signalling systems. Its antidepressant mechanism is not fully understood. Research and guidelines support discussion of ketamine as an advanced option in selected difficult-to-treat depression cases, but a rapid response is not guaranteed. A strong subjective experience during an infusion does not establish lasting benefit.

A psychiatrist reviews the depressive illness, adequate previous treatment trials, current risk, other diagnoses and the alternatives. The assessment also reviews cardiovascular health, substance-use risks, pregnancy, liver history and medicines that may affect sedation or blood pressure. The clinician should explain why off-label IV ketamine is being considered and how outcomes and harms will be assessed. A suicidal crisis needs urgent safety care independently of a planned infusion.

Ketamine can cause sedation, dissociation, higher blood pressure and breathing problems. Misuse and dependence risks, urinary symptoms and other adverse effects require discussion, especially with repeated exposure. MedlinePlus advises no driving or machinery for at least 24 hours after ketamine injection. Follow any longer restriction from the treating clinician. Call 911 for breathing difficulty, fainting or a serious allergic reaction. Report urinary pain, troubling confusion or worsening mood to the treating clinician.

Track changes in mood, daily function, adverse effects and the duration of any improvement. If symptoms return between sessions, contact the treating psychiatrist rather than arranging an unsupervised dose increase. There is no Spravato-label maintenance schedule that can simply be applied to IV ketamine. A switch between formulations requires a new clinical and practical review.

Bring the treatment history and a full medicine and substance-use list. Obtain the program’s written eating, drinking and medication instructions. Do not substitute the Spravato food rules for an infusion protocol. Arrange transport home and time away from driving and hazardous work. Ask about support after discharge, responsibilities later that day and whom to call about a concerning symptom.

Ask about the intended condition, expected benefit, uncertainty and alternatives such as established medicines, psychotherapy or a referral for brain stimulation. Off-label prescribing is a clinical decision. It does not mean FDA has approved a depression dose or schedule.

Ask who will administer and monitor the infusion, how breathing, blood pressure and alertness will be assessed, and how an emergency will be handled. Do not transfer onsite infusion information to an unsupervised home or compounded nasal regimen.

Before starting, agree on symptom and function measures, when benefit will be reviewed and what happens if there is little improvement or adverse effects. Session numbers and maintenance intervals must come from the treating program. They cannot be inferred from the Spravato label.

Ask about the intended condition, expected benefit, uncertainty and alternatives such as established medicines, psychotherapy or a referral for brain stimulation. Off-label prescribing is a clinical decision. It does not mean FDA has approved a depression dose or schedule.

Ask who will administer and monitor the infusion, how breathing, blood pressure and alertness will be assessed, and how an emergency will be handled. Do not transfer onsite infusion information to an unsupervised home or compounded nasal regimen.

Before starting, agree on symptom and function measures, when benefit will be reviewed and what happens if there is little improvement or adverse effects. Session numbers and maintenance intervals must come from the treating program. They cannot be inferred from the Spravato label.

Ketamine can cause sedation, dissociation, higher blood pressure and breathing problems. Misuse and dependence risks, urinary symptoms and other adverse effects require discussion, especially with repeated exposure. MedlinePlus advises no driving or machinery for at least 24 hours after ketamine injection. Follow any longer restriction from the treating clinician. Call 911 for breathing difficulty, fainting or a serious allergic reaction. Report urinary pain, troubling confusion or worsening mood to the treating clinician.

Track changes in mood, daily function, adverse effects and the duration of any improvement. If symptoms return between sessions, contact the treating psychiatrist rather than arranging an unsupervised dose increase. There is no Spravato-label maintenance schedule that can simply be applied to IV ketamine. A switch between formulations requires a new clinical and practical review.

The formulation and regulatory status differ, and insurers apply different benefits and authorization rules. Obtain a plan-specific determination and written estimate rather than relying on another patient’s claim history.

Contact the treating psychiatrist for reassessment of symptoms, safety and the treatment plan. Do not switch routes, increase frequency or add compounded ketamine yourself.

Ketamine is a dissociative anesthetic, not an opioid. It is a Schedule III controlled medicine. Injectable ketamine is FDA approved for anesthesia; its use for depression is off-label. Spravato is a different esketamine nasal-spray product with specific adult depression indications and a supervised REMS program. Ketamine can cause sedation, altered perception, higher blood pressure and breathing problems, and carries misuse and dependence risks. The formulation and monitored setting matter.

Yes. Ketamine can temporarily change perception and cause dissociation, which may feel like being detached from your body or surroundings. It can also cause sleepiness, confusion or distress. A strong subjective experience is not a measure of antidepressant benefit, and trying to intensify it increases risk. Treatment requires assessment, appropriate monitoring and a plan for safe travel afterward. Tell the treating clinician about a frightening experience or persistent confusion.

Ketamine blocks NMDA receptors, which are involved in glutamate signalling in the brain. Ketamine injection is an anesthetic medicine and is also sometimes used off label for depression that has resisted other medicines. Its use for depression needs a separate clinical discussion of benefits, risks and monitoring; the anesthetic label does not establish an FDA-approved depression indication.